T Chiang1, K Sansuk, R M van Rijn. 1. Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University, West Lafayette, IN, USA
Abstract
BACKGROUND AND PURPOSE: δ Opioid receptor agonists are being developed as potential treatments for depression and alcohol use disorders. This is particularly interesting as depression is frequently co-morbid with alcohol use disorders. Yet we have previously shown that δ receptor agonists range widely in their ability to modulate alcohol intake; certain δ receptor agonists actually increase alcohol consumption in mice. We propose that variations in β-arrestin 2 recruitment contribute to the differential behavioural profile of δ receptor agonists. EXPERIMENTAL APPROACH: We used three diarylmethylpiperazine-based non-peptidic δ receptor selective agonists (SNC80, SNC162 and ARM390) and three structurally diverse δ receptor agonists (TAN-67, KNT127 and NIH11082). We tested these agonists in cAMP and β-arrestin 2 recruitment assays and a behavioural assay of alcohol intake in male C57BL/6 mice. We used β-arrestin 2 knockout mice and a model of depression-like behaviour to further study the role of β-arrestin 2 in δ receptor pharmacology. KEY RESULTS: All six tested δ receptor agonists were full agonists in the cAMP assay but displayed distinct β-arrestin 2 recruitment efficacy. The efficacy of δ receptor agonists to recruit β-arrestin 2 positively correlated with their ability to increase alcohol intake (P < 0.01). The effects of the very efficacious recruiter SNC80 on alcohol intake, alcohol place preference and depression-like behaviour were β-arrestin 2-dependent. CONCLUSIONS AND IMPLICATIONS: Our finding that δ receptor agonists that strongly recruit β-arrestin 2 can increase alcohol intake carries important ramifications for drug development of δ receptor agonists for treatment of alcohol use disorders and depressive disorders.
BACKGROUND AND PURPOSE: δ Opioid receptor agonists are being developed as potential treatments for depression and alcohol use disorders. This is particularly interesting as depression is frequently co-morbid with alcohol use disorders. Yet we have previously shown that δ receptor agonists range widely in their ability to modulate alcohol intake; certain δ receptor agonists actually increase alcohol consumption in mice. We propose that variations in β-arrestin 2 recruitment contribute to the differential behavioural profile of δ receptor agonists. EXPERIMENTAL APPROACH: We used three diarylmethylpiperazine-based non-peptidic δ receptor selective agonists (SNC80, SNC162 and ARM390) and three structurally diverse δ receptor agonists (TAN-67, KNT127 and NIH11082). We tested these agonists in cAMP and β-arrestin 2 recruitment assays and a behavioural assay of alcohol intake in male C57BL/6 mice. We used β-arrestin 2 knockout mice and a model of depression-like behaviour to further study the role of β-arrestin 2 in δ receptor pharmacology. KEY RESULTS: All six tested δ receptor agonists were full agonists in the cAMP assay but displayed distinct β-arrestin 2 recruitment efficacy. The efficacy of δ receptor agonists to recruit β-arrestin 2 positively correlated with their ability to increase alcohol intake (P < 0.01). The effects of the very efficacious recruiter SNC80 on alcohol intake, alcohol place preference and depression-like behaviour were β-arrestin 2-dependent. CONCLUSIONS AND IMPLICATIONS: Our finding that δ receptor agonists that strongly recruit β-arrestin 2 can increase alcohol intake carries important ramifications for drug development of δ receptor agonists for treatment of alcohol use disorders and depressive disorders.
Authors: D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer Journal: Nat Genet Date: 2000-06 Impact factor: 38.330
Authors: R M Quock; Y Hosohata; R J Knapp; T H Burkey; K Hosohata; X Zhang; K C Rice; H Nagase; V J Hruby; F Porreca; W R Roeske; H I Yamamura Journal: Eur J Pharmacol Date: 1997-05-12 Impact factor: 4.432
Authors: Emily M Jutkiewicz; Sarah T Kaminsky; Kenner C Rice; John R Traynor; James H Woods Journal: J Pharmacol Exp Ther Date: 2005-07-13 Impact factor: 4.030
Authors: Chihiro Nozaki; Bertrand Le Bourdonnec; David Reiss; Rolf T Windh; Patrick J Little; Roland E Dolle; Brigitte L Kieffer; Claire Gavériaux-Ruff Journal: J Pharmacol Exp Ther Date: 2012-06-13 Impact factor: 4.030
Authors: M Alexander Stanczyk; Kathryn E Livingston; Louise Chang; Zara Y Weinberg; Manojkumar A Puthenveedu; John R Traynor Journal: Br J Pharmacol Date: 2019-04-14 Impact factor: 8.739
Authors: Isaac J Dripps; Qin Wang; Richard R Neubig; Kenner C Rice; John R Traynor; Emily M Jutkiewicz Journal: Psychopharmacology (Berl) Date: 2016-09-13 Impact factor: 4.530